
JAK inhibitor prevents GvHD in ‘half-matched’ stem cell transplants
Adding a new drug to standard care for stem cell transplant recipients may reduce graft-versus-host disease (GvHD), according to an early-stage clinical trial conducted at Washington University School of Medicine in St Louis. The trial showed that patients being treated for various blood cancers tolerated the… Read More












